ID: ALA1688383
Chembl Id: CHEMBL1688383
PubChem CID: 25006094
Max Phase: Preclinical
Molecular Formula: C21H28N2O3
Molecular Weight: 356.47
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCN(c1ccc(C(C)C)c(OCC(C)C)c1)c1ccc(C(=O)O)cn1
Standard InChI: InChI=1S/C21H28N2O3/c1-6-23(20-10-7-16(12-22-20)21(24)25)17-8-9-18(15(4)5)19(11-17)26-13-14(2)3/h7-12,14-15H,6,13H2,1-5H3,(H,24,25)
Standard InChI Key: JUCWZKDTWSKUAW-UHFFFAOYSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 356.47 | Molecular Weight (Monoisotopic): 356.2100 | AlogP: 5.10 | #Rotatable Bonds: 8 |
| Polar Surface Area: 62.66 | Molecular Species: ACID | HBA: 4 | HBD: 1 |
| #RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 2.86 | CX Basic pKa: 4.28 | CX LogP: 4.70 | CX LogD: 2.11 |
| Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.71 | Np Likeness Score: -0.94 |
| 1. Ohsawa F, Morishita K, Yamada S, Makishima M, Kakuta H.. (2010) Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers., 1 (9): [PMID:24900241] [10.1021/ml100184k] |
| 2. Nakayama M, Yamada S, Ohsawa F, Ohta Y, Kawata K, Makishima M, Kakuta H.. (2011) Discovery of a Potent Retinoid X Receptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB., 2 (12): [PMID:24900278] [10.1021/ml200197e] |
| 3. Kobayashi T, Furusawa Y, Yamada S, Akehi M, Takenaka F, Sasaki T, Akahoshi A, Hanada T, Matsuura E, Hirano H, Tai A, Kakuta H.. (2015) Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists., 6 (3): [PMID:25815156] [10.1021/ml500511m] |
| 4. Yamada S, Kawasaki M, Fujihara M, Watanabe M, Takamura Y, Takioku M, Nishioka H, Takeuchi Y, Makishima M, Motoyama T, Ito S, Tokiwa H, Nakano S, Kakuta H.. (2019) Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening., 62 (19): [PMID:31483660] [10.1021/acs.jmedchem.9b00995] |
| 5. Kawasaki M, Motoyama T, Yamada S, Watanabe M, Fujihara M, Kambe A, Nakano S, Kakuta H, Ito S.. (2023) Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN., 14 (3): [PMID:36923911] [10.1021/acsmedchemlett.2c00509] |
Source(1):
